TY  - GEN
AU  - de Lima,M
AU  - Champlin,R E
AU  - Thall,P F
AU  - Wang,X
AU  - Martin,T G
AU  - Cook,J D
AU  - McCormick,G
AU  - Qazilbash,M
AU  - Kebriaei,P
AU  - Couriel,D
AU  - Shpall,E J
AU  - Khouri,I
AU  - Anderlini,P
AU  - Hosing,C
AU  - Chan,K W
AU  - Andersson,B S
AU  - Patah,P A
AU  - Caldera,Z
AU  - Jabbour,E
AU  - Giralt,S
TI  - Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome
SN  - 1476-5551
PY  - 2008///0326
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Aminoglycosides
KW  - administration & dosage
KW  - Antibodies, Monoclonal
KW  - Antibodies, Monoclonal, Humanized
KW  - Antigens, CD
KW  - Antigens, Differentiation, Myelomonocytic
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Disease-Free Survival
KW  - Female
KW  - Gemtuzumab
KW  - Graft Survival
KW  - Hematopoietic Stem Cell Transplantation
KW  - methods
KW  - Humans
KW  - Leukemia, Myeloid
KW  - mortality
KW  - Male
KW  - Melphalan
KW  - Middle Aged
KW  - Myelodysplastic Syndromes
KW  - Remission Induction
KW  - Sialic Acid Binding Ig-like Lectin 3
KW  - Survival Rate
KW  - Transplantation, Homologous
KW  - Vidarabine
N1  - Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
UR  - https://doi.org/10.1038/sj.leu.2405014
ER  -